Connect to share and comment

Bayer seeks wider use for eye drug Eylea in Europe

PlacardEnlarge
(GlobalPost/GlobalPost)

FRANKFURT (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.

Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.

The injection, which Bayer is co-developing with Regeneron, is already approved for other eye diseases. ($1 = 0.7392 euros)

(Reporting by Ludwig Burger; Editing by Christoph Steitz)

http://www.globalpost.com/dispatch/news/thomson-reuters/131107/bayer-seeks-wider-use-eye-drug-eylea-europe